TG Therapeutics Inc (TGTX) CFO Sells $272,051.00 in Stock

TG Therapeutics Inc (NASDAQ:TGTX) CFO Sean A. Power sold 32,006 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares in the company, valued at $4,398,444. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

TG Therapeutics Inc (TGTX) traded up $0.50 during trading hours on Wednesday, reaching $9.25. The company’s stock had a trading volume of 1,851,729 shares, compared to its average volume of 1,576,750. TG Therapeutics Inc has a one year low of $4.10 and a one year high of $15.35. The stock has a market capitalization of $653.53, a price-to-earnings ratio of -4.79 and a beta of 1.30.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.05). The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. equities research analysts expect that TG Therapeutics Inc will post -1.87 EPS for the current fiscal year.

Several research analysts have commented on TGTX shares. HC Wainwright reissued a “buy” rating and issued a $33.00 price objective (up from $18.00) on shares of TG Therapeutics in a research report on Tuesday, November 14th. B. Riley started coverage on TG Therapeutics in a research report on Friday, December 1st. They issued a “buy” rating and a $21.50 price objective on the stock. ValuEngine lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Raymond James Financial reissued a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, December 12th. Finally, SunTrust Banks reissued a “buy” rating and issued a $28.00 price objective on shares of TG Therapeutics in a research report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. TG Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.50.

Institutional investors have recently made changes to their positions in the company. Legal & General Group Plc grew its stake in shares of TG Therapeutics by 14.9% during the second quarter. Legal & General Group Plc now owns 11,264 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 1,463 shares in the last quarter. BB&T Securities LLC grew its stake in shares of TG Therapeutics by 63.0% during the second quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock valued at $170,000 after acquiring an additional 6,549 shares in the last quarter. Voya Investment Management LLC grew its stake in shares of TG Therapeutics by 40.2% during the second quarter. Voya Investment Management LLC now owns 22,521 shares of the biopharmaceutical company’s stock valued at $226,000 after acquiring an additional 6,463 shares in the last quarter. Nationwide Fund Advisors grew its stake in shares of TG Therapeutics by 24.2% during the second quarter. Nationwide Fund Advisors now owns 26,531 shares of the biopharmaceutical company’s stock valued at $267,000 after acquiring an additional 5,167 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of TG Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 36,754 shares of the biopharmaceutical company’s stock valued at $370,000 after acquiring an additional 7,630 shares in the last quarter. Institutional investors own 50.41% of the company’s stock.

WARNING: “TG Therapeutics Inc (TGTX) CFO Sells $272,051.00 in Stock” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/03/tg-therapeutics-inc-tgtx-cfo-sells-272051-00-in-stock.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply